Ischemic stroke is the second leading cause of death worldwide, and there are limited effective treatment strategies. QHRD106, a polyethyleneglycol...
Array
(
[id_prestablog_news] => 1842
[id_shop] => 1
[date] => 2023-07-03 00:00:00
[date_modification] => 2024-02-09 14:15:13
[langues] => ["1","2"]
[actif] => 1
[slide] => 0
[url_redirect] =>
[average_rating] =>
[number_rating] =>
[author_id] => 1
[featured] => 0
[prim_key] => 3363
[id_lang] => 2
[title] => QHRD106 ameliorates ischemic stroke injury as a long-acting tissue kallikrein pr
[paragraph] => QHRD106 ameliorates ischemic stroke injury as a long-acting tissue kallikrein preparation
[content] => Authors
Xu SY, Jia JQ, Sun M, Bao XY, Xia SN, Shu S, Liu PY, Ji SL, Ye L, Cao X, Xu Y.
Lab
Nanjing Neurology Medical Center, Nanjing, Jiangsu 210008, P.R. China.
Journal
iScience
Abstract
Ischemic stroke is the second leading cause of death worldwide, and there are limited effective treatment strategies. QHRD106, a polyethyleneglycol (PEG)-modified long-acting tissue kallikrein preparation, has not been reported previously. In this study, we aimed to investigate the therapeutic effect of QHRD106 in ischemic stroke and its possible mechanism. We found that QHRD106 treatment alleviated brain injury after stroke via bradykinin (BK) receptor B2 (B2R) instead of BK receptor B1 (B1R). Mechanistically, QHRD106 reduced high-mobility group box 1 (HMGB1)-induced apoptosis and inflammation after ischemic stroke in vivo and in vitro. Moreover, we confirmed that QHRD106 reduced the level of acetylated HMGB1 and reduced the binding between heat shock protein 90 alpha family class A member 1 (HSP90AA1) and HMGB1, thus inhibiting the translocation and release of HMGB1. In summary, these findings indicate that QHRD106 treatment has therapeutic potential for cerebral ischemic stroke.
BIOSEB Instruments Used
Grip strength test (BIO-GS4)
[meta_description] =>
[meta_keywords] => https://www.cell.com/iscience/pdf/S2589-0042(23)01345-7.pdf
[meta_title] =>
[link_rewrite] => qhrd106-ameliorates-ischemic-stroke-injury-as-a-long-acting-tissue-kallikrein-preparation
[actif_langue] => 1
[read] => 509
[count_comments] => 0
[id] => 1842
[categories] => Array
(
[40] => Array
(
[id_prestablog_categorie] => 40
[title] => Accidents ischémiques transitoires (AIT)
[link_rewrite] => Accidents-ischemiques-transitoires-AIT
)
[2] => Array
(
[id_prestablog_categorie] => 2
[title] => Publications
[link_rewrite] => publications
)
)
[authors] =>
[paragraph_crop] => QHRD106 ameliorates ischemic stroke injury as a long-acting tissue kallikrein preparation
[link_for_unique] => 1
[products_liaison] => Array
(
[48] => Array
(
[name] => Test d'agrippement
[description_short] => Une méthode simple pour quantifier objectivement la force musculaire des rats et souris et l'effet de drogues, toxines, maladies musculaires (ex: myopathie) et neurodégénératives. Cette mesure de force est souvent employée en association avec le test de coordination motrice ROTAROD: un sujet présentant une coordination normale montrera des résultats médiocres en cas de faible force musculaire. Un must pour vos recherches sur l'activité, la coordination et le contrôle musculaire: particulièrement utile pour vos études sur les maladies de Parkinson et Huntington.
Nouveautés GS4 - 2023: Écran couleur rétroéclairé (meilleure lisibilité), pédale de remise à zéro, durée de batterie optimisée, taille de mémoire augmentée à 500 valeurs, compteur d'animaux, port USB (transfert de données/charge)


[thumb] =>
[img_empty] => /var/www/vhosts/de3310.ispfr.net/bioseb2024/modules/prestablog/views/img/product_link_white.jpg
[image_presente] => 1
[link] => https://bioseb.com/fr/activite-systeme-moteur-coordination/48-grip-strength-test.html
)
)
)
1 En lire plus